Genevieve Desjardins

Associate Director in Protein Engineering at Zymeworks Inc

Speaker

Genevieve Desjardins is an Associate Director in Protein Engineering at Zymeworks, where she contributes to the discovery and development of next-generation multispecific antibody therapeutics. Her work in protein engineering has supported multiple clinical-stage programs, including Ziihera® (zanidatamab), a biparatopic HER2 targeted antibody, ZW171, a mesothelin targeted T cell engager, as well as ZW209, a DLL3-targeted T cell engager with CD28 co-stimulation. Her contribution spans from early discovery through IND filing with a focus on engineering robust therapeutic molecules to tackle complex biological problems. Genevieve has over a decade of industry experience working on antibody drug development, platform engineering and leading programs across oncology and immunology indications. Her contributions have helped drive innovative approaches to multispecific design, including optimization of format, affinity, stability, and manufacturability. Genevieve is passionate about translating cutting-edge protein engineering technologies into impactful medicines for patients and actively engages in scientific collaboration and knowledge sharing within the biotech community.